CompletedPhase 2

Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients

Egypt40 participantsStarted 2024-08-01

Plain-language summary

investigating the potential effect of Coenzyme Q10 in ameliorating and preventing the development of paclitaxel chemotherapeutic toxicity in breast cancer patients

Who can participate

Age range18 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. women with newly diagnosed breast cancer r ≥18 years old.
✓. Naive to chemotherapy.
✓. Eastern Cooperative Oncology Group (ECOG) performance status from 0-2

Exclusion criteria

✕. Advanced liver disease (defined as liver enzyme elevation \>3-fold upper limit of normality, or cirrhosis); chronic kidney disease (CKD, defined as an estimated glomerular filtration rate (eGFR) \<60 ml min-1 1.73 m-2).
✕. Patients with a history of allergy to Coenzyme Q10 and similar compounds.
✕. Concomitant use of opioids, anticonvulsants, tricyclic antidepressants, other neuropathic pain medication.
✕. Pregnancy or breast feeding.
✕. hereditary muscle disorders.

What they're measuring

Number of Participants With Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0

Timeframe: 3 months

Trial details

NCT IDNCT06570811

SponsorDamanhour University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-10

View on ClinicalTrials.gov More Breast Cancer trials